Trends in survival after a diagnosis of heart failure in the United Kingdom 2000-2017: population based cohort study. Taylor CJ, Ordóñez-Mena JM, Roalfe AK, et al. Heart failure: Understanding heart failure.Īmerican Heart Association. This doesn’t mean you don’t have heart failure anymore. Sometimes, you may have mild symptoms of congestive heart failure or none at all. Impact of blood volume quantification on decongestion strategy, readmission rates (RR), and mortality in hospitalized heart failure patients (HHF). Google Scholar 10 Strobeck JE, Miller WL. Prediction of sudden death in elderly patients with heart failure. Loss of appetite or upset stomach ( nausea ). Fluid volume overload and congestion in heart failure: time to reconsider pathophysiology and how volume is assessed. doi:10.1002/ejhf.872Īyesta A, Martínez-sellés H, Bayés de luna A, Martínez-sellés M. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. Harjola VP, Mullens W, Banaszewski M, et al. Heart Failure as a Risk Factor for Stroke. Pulmonary complications of congenital heart disease. Management of Arrhythmias in Heart Failure. Masarone D, Limongelli G, Rubino M, et al. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG). Pedal Edema as an Indicator of Early Heart Failure in the Community: Prevalence and Associations With Cardiac Structure/Function and Natriuretic Peptides (MESA ). Intrathoracic impedance vs daily weight monitoring for predicting worsening heart failure events: results of the Fluid Accumulation Status Trial (FAST). Fluid Volume Overload and Congestion in Heart Failure: Time to Reconsider Pathophysiology and How Volume Is Assessed. Finally, we will present recent studies challenging the common notion that TZDs worsen renal salt and water retention in CHF.Ĭongestive heart failure Diabetes mellitus Fluid retention Kidney Peroxisome proliferator-activated receptor-γ Thiazolidinediones.Ĭopyright © 2016 Elsevier Inc. Moreover, we thoroughly review the available data on TZD-induced fluid retention and proposed mechanisms in animals and patients. In an attempt to elucidate whether TZDs actually exacerbate the pre-existing fluid retention in CHF, our review summarizes the pathophysiology of fluid retention in CHF. Lung cancer, breast cancer, melanoma, and lymphoma can cause fluid to build up around your heart. However, despite a considerable body of evidence on mechanisms responsible for TZD-induced fluid retention suggesting that this class of drugs is rightfully prohibited from use in CHF patients, there is a paucity of experimental and clinical studies that investigate the effects of TZDs on salt and water homeostasis in the CHF setting. Certain cancers can cause a pericardial effusion. Presumably, the latter effects are potentially deleterious in the context of pre-existing fluid retention in CHF. However, the utility of TZDs in T2DM has declined in the past decade, largely due to concomitant adverse effects of fluid retention and edema formation attributed to salt-retaining effects of PPARγ activation on the nephron. The thiazolidinedione (TZD) family of peroxisome proliferator-activated receptor γ (PPARγ) agonists initially provided a promising therapeutic option in T2DM owing to anti-diabetic efficacy combined with pleiotropic beneficial cardiovascular effects. The ever-growing global burden of congestive heart failure (CHF) and type 2 diabetes mellitus (T2DM) as well as their co-existence necessitate that anti-diabetic pharmacotherapy will modulate the cardiovascular risk inherent to T2DM while complying with the accompanying restrictions imposed by CHF.
0 Comments
Leave a Reply. |